Ozempic Maker Says a Heart Aging Clock Read Up to 4 Years Younger | Longevity News

In early data, the maker of Ozempic says its drug made a heart aging clock read up to four years younger. Here's what was actually measured, plus two more things you might have missed in longevity this week. At the ARDD aging conference in Boston, the makers of Ozempic and Zepbound presented early aging-clock data. Novo Nordisk's analysis, an unreviewed preprint, pooled blood-protein clocks from 10,052 people across five placebo-controlled semaglutide trials. Compared with placebo, a heart clock read roughly two to four years younger, and kidney, brain and whole-body clocks one to four years younger. Eli Lilly's smaller tirzepatide sub-study was presented only at the conference and had no placebo group: in 82 people over about 1.4 years, all 15 epigenetic clocks showed less aging than the time that passed, but only two were statistically significant. Aging clocks are estimates, not proof that anyone lives longer. Clock pioneer Steve Horvath called the effect "pretty strong" but said he has not yet seen enough evidence that the drugs help lean people. ARPA-H is funding trials in Texas in healthy older adults. Last week we covered FDA officials at the same conference saying aging will be one topic in a planned regulatory-science document. On one of these drugs and worried about hair loss? Full breakdown: https://youtu.be/7otg75BINSo Also this week: - Life Biosciences, co-founded by David Sinclair, reported first human data for ER-100, an eye gene therapy that switches on three Yamanaka factors (OSK) to try to restore retinal nerve cells in glaucoma. Very early and open-label: three patients at the starting dose, no serious side effects through day 56, and in two of them at least 28% of tested visual-field points improved. A safety board cleared a higher dose. - A randomized, double-blind Texas A&M trial in 64 adults aged 45 to 65 suggests creatine may add lean tissue over 12 weeks even without exercise (about 2.4 lb in the non-exercise group). Critics say much of that may be water, which DEXA scans count as lean tissue, and point out that participants chose their own exercise group. Sources: https://www.technologyreview.com/2026/10/06/1145836/weight-loss-drugs-glp1-lilly-novo-aging-clocks/ https://longevity.technology/news/lilly-and-novo-share-glp-1-longevity-data/ https://www.medicaldaily.com/glp1-aging-clocks-novo-lilly-unreviewed-data-479718 https://longevity.technology/news/cellular-rejuvenation-reaches-a-human-trial/ https://www.lifebiosciences.com/life-biosciences-announces-first-in-human-data-from-ongoing-phase-1-trial-evaluating-er-100-in-optic-neuropathies/ https://www.sciencedaily.com/releases/2026/09/260928100547.htm https://www.isrctn.com/ISRCTN83081058 Follow for the longevity news every week, and tell us in the comments what you want covered next. Informational only. Talk to your doctor before making changes.